EP1225907A4 - Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions - Google Patents

Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions

Info

Publication number
EP1225907A4
EP1225907A4 EP20000972031 EP00972031A EP1225907A4 EP 1225907 A4 EP1225907 A4 EP 1225907A4 EP 20000972031 EP20000972031 EP 20000972031 EP 00972031 A EP00972031 A EP 00972031A EP 1225907 A4 EP1225907 A4 EP 1225907A4
Authority
EP
Grant status
Application
Patent type
Prior art keywords
peptide
nucleic acid
immune responses
immunodeficiency virus
human immunodeficiency
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP20000972031
Other languages
German (de)
French (fr)
Other versions
EP1225907A1 (en )
Inventor
Alessandro Sette
John Sidney
Scott Southwood
Brian D Livingston
Robert Chesnut
Denise Marie Baker
Esteban Celis
Ralph T Kubo
Howard M Grey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Epimmune Inc
Original Assignee
Epimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells, macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5158Antigen-pulsed cells, e.g. T-cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/57Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16111Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16211Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse Transcribing RNA Viruses
    • C12N2740/00011Reverse Transcribing RNA Viruses
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16311Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
EP20000972031 1999-10-05 2000-10-05 Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions Withdrawn EP1225907A4 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US41286399 true 1999-10-05 1999-10-05
US412863 1999-10-05
PCT/US2000/027766 WO2001024810A1 (en) 1999-10-05 2000-10-05 Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions

Publications (2)

Publication Number Publication Date
EP1225907A1 true EP1225907A1 (en) 2002-07-31
EP1225907A4 true true EP1225907A4 (en) 2005-06-22

Family

ID=23634801

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20000972031 Withdrawn EP1225907A4 (en) 1999-10-05 2000-10-05 Inducing cellular immune responses to human immunodeficiency virus-1 using peptide and nucleic acid compositions

Country Status (4)

Country Link
EP (1) EP1225907A4 (en)
JP (1) JP4873810B2 (en)
CA (1) CA2386499A1 (en)
WO (1) WO2001024810A1 (en)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462354B2 (en) * 1999-12-28 2008-12-09 Pharmexa Inc. Method and system for optimizing minigenes and peptides encoded thereby
US7790171B1 (en) * 2000-08-25 2010-09-07 Centre National De La Recherche Scientifique (C.N.R.S.) Antiviral peptides obtained from the tryptophan-rich hydrophobic cluster of the HIV-1 reverse transcriptase
FR2824326B1 (en) * 2001-05-04 2004-03-19 Commissariat Energie Atomique Mixture of peptides derived from protein E6 and / or E7 of HPV and their applications
ES2274100T3 (en) 2001-09-07 2007-05-16 Polymun Scientific Immunbiologische Forschung Gmbh Antibodies that recognize a peptide that mimics a cryptic epitope of gp41 of HIV-1.
CA2357906A1 (en) 2001-09-28 2003-03-28 Institut Pasteur Identification of new cd8 epitopes from hiv-1 proteins with therapeutical and vaccinal properties against hiv infections
WO2003029475A1 (en) * 2001-09-28 2003-04-10 Dnavec Research Inc. MAMMALIAN CELL-INFECTING VIRUS VECTOR ENCODING EPITOPE-BOUND β2m AND UTILIZATION THEREOF
EP2014674B1 (en) * 2001-11-26 2014-02-12 Laboratoire Biodim Protein-protein interactions in human immunodeficiency virus
WO2003066663A3 (en) * 2002-02-04 2004-01-29 Henry J Baker Peptides for recognition and targeting of glial cell tumors
EP1431306A1 (en) * 2002-12-19 2004-06-23 Creabilis Therapeutics s.r.l. A mechanism for hiv-1 entry into host cells and peptides inhibiting this mechanism
WO2004085466A8 (en) 2003-03-28 2005-10-13 Us Gov Health & Human Serv Immunogenic hiv-1 multi-clade, multivalent constructs and methods of their use
CA2520768A1 (en) * 2003-03-28 2005-02-10 Idm Pharma, Inc. Methods of identifying optimal variants of peptide epitopes
WO2004106365A3 (en) * 2003-05-28 2005-06-23 Aventis Pasteur Inc Modulatory peptide motifs for inducing th1 or th2 immune response
US7771726B2 (en) * 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
US7786288B2 (en) * 2003-10-23 2010-08-31 Karp Nelson M Immunizing compositions encoding an epitope obtained from the HIV-1 capsid protein cyclophilin A binding site
US7999071B2 (en) 2003-12-12 2011-08-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human cytotoxic T-lymphoctye epitope and its agonist eptiope from the non-variable number of tandem repeat sequence of MUC-1
WO2005116055A1 (en) * 2004-05-24 2005-12-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Peptides, antibodies and compositions containing same useful for treating hiv virus infection
FR2874612A1 (en) * 2004-08-27 2006-03-03 Commissariat Energie Atomique Cd4 + T epitopes of HIV has restricted hla-dp4 and applications
US8029797B2 (en) 2005-03-01 2011-10-04 Variation Biotechnologies Inc. Multivalent HIV immunogenic compositions comprising a pool of lipidated and nonlipidated peptides representing Gag and Env variable regions
US7501398B2 (en) * 2005-07-22 2009-03-10 Universita'degli Studi Di Milano Inhibitor of the folding of the HIV-1-protease as antiviral agent
EP2021356B1 (en) * 2006-06-01 2010-10-27 Statens Serum Institut Hiv vaccine
WO2008068765A3 (en) * 2006-12-07 2008-12-11 Yissum Res Dev Co Compositions and methods for inhibiting hiv-1 replication and integrase activity
KR101580660B1 (en) 2007-08-02 2015-12-28 바이오앤드백스 파마슈티칼즈, 리미티드. Multimeric multiepitope influenza vaccines
JP2010536885A (en) * 2007-08-24 2010-12-02 ノバルティス アーゲー hivenv proteins with altered to V3 loop
WO2009043155A3 (en) * 2007-10-03 2009-05-28 Ca Minister Health & Welfare Distinct hiv-1 gag and env epitopes of hla alleles associated with differential susceptibility to hiv-1 infection
WO2010011343A3 (en) * 2008-07-25 2010-05-14 The Regents Of The University Of Colorado Methods for treating viral disorders
US9163067B2 (en) * 2008-10-06 2015-10-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd HIV-1 integrase derived stimulatory peptides interfering with integrase—Rev protein binding
JP5792630B2 (en) 2009-01-28 2015-10-14 エピミューン,インコーポレイティド Pan-dr binding polypeptides and uses thereof
CA2768149A1 (en) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for hiv disease
ES2358829B1 (en) 2009-10-23 2012-06-25 Lipotec, S.A. Peptides useful in the treatment and / or care of skin, mucous membranes and / or hair and use in cosmetic or pharmaceutical compositions.
EP2452947A1 (en) * 2010-11-16 2012-05-16 Münch, Jan Viral infection enhancing peptide
CA2828068A1 (en) 2011-02-22 2012-08-30 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
EP2694654B1 (en) * 2011-04-07 2018-01-24 Her Majesty The Queen In Right of Canada as represented by The Minister of Health Protease cleavage site peptides as an hiv vaccine
EP2745845A1 (en) 2012-12-19 2014-06-25 Centre Hospitalier Universitaire de Bordeaux A method for preventing or treating an HIV infection
GB201322574D0 (en) * 2013-12-19 2014-02-05 Equigerminal Sa Retroviral peptides
KR101476255B1 (en) * 2014-02-07 2014-12-26 대한민국 Recombinant peptide having T cell epitope derived from HIV-1 and vaccine composition comprising thereof
WO2017093985A4 (en) * 2015-12-05 2017-07-27 Centre Hospitalier Universitaire Vaudois Hiv binding agents
GB2549798A (en) * 2016-04-29 2017-11-01 Univ Bradford Peptides and nanoparticle formulations thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A2 (en) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of HIV-1 infection
WO1992022577A1 (en) * 1991-06-17 1992-12-23 Neovacs Immunogen compounds having specifically an anti-cytokine effect, method of preparation, pharmaceutical compositions and kits containing them
WO1997034617A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla binding peptides and their uses
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
US5736142A (en) * 1993-09-14 1998-04-07 Cytel Corporation Alteration of immune response using pan DR-binding peptides
WO1999049893A1 (en) * 1998-03-31 1999-10-07 Trustees Of Boston University Methods for designing molecular conjugates and compositions thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE68925660T2 (en) * 1988-06-10 1996-09-26 United Biomedical Inc Peptide fragments of HIV
US6419931B1 (en) * 1991-08-26 2002-07-16 Epimmune Inc. Compositions and methods for eliciting CTL immunity
US5756666A (en) * 1993-10-19 1998-05-26 Ajinomoto Co., Inc. Peptides capable of inducing immune response to HIV
US6413517B1 (en) * 1997-01-23 2002-07-02 Epimmune, Inc. Identification of broadly reactive DR restricted epitopes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330359A2 (en) * 1988-02-25 1989-08-30 Bio-Rad Laboratories, Inc. Composition useful in the diagnosis and treating of HIV-1 infection
WO1992022577A1 (en) * 1991-06-17 1992-12-23 Neovacs Immunogen compounds having specifically an anti-cytokine effect, method of preparation, pharmaceutical compositions and kits containing them
US5696238A (en) * 1991-08-20 1997-12-09 Chiron Corporation Purified GP120 composition retaining natural conformation
US5736142A (en) * 1993-09-14 1998-04-07 Cytel Corporation Alteration of immune response using pan DR-binding peptides
WO1997034617A1 (en) * 1996-03-21 1997-09-25 Cytel Corporation Hla binding peptides and their uses
WO1999049893A1 (en) * 1998-03-31 1999-10-07 Trustees Of Boston University Methods for designing molecular conjugates and compositions thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE GSP 11 August 1998 (1998-08-11), retrieved from EBI Database accession no. AAW43064 *
DATABASE GSP 12 May 1993 (1993-05-12), retrieved from EBI Database accession no. AAR30963 *
DATABASE GSP 21 February 1990 (1990-02-21), retrieved from EBI Database accession no. AAP90212 *
See also references of WO0124810A1 *

Also Published As

Publication number Publication date Type
JP4873810B2 (en) 2012-02-08 grant
WO2001024810A1 (en) 2001-04-12 application
EP1225907A1 (en) 2002-07-31 application
CA2386499A1 (en) 2001-04-12 application
JP2003510099A (en) 2003-03-18 application

Similar Documents

Publication Publication Date Title
GB2248550B (en) hPTH (1-36) Peptides,their preparation and pharmaceutical compositions
GB9713077D0 (en) Improvements relating to skin prickers

Legal Events

Date Code Title Description
17P Request for examination filed

Effective date: 20020502

AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent to

Free format text: AL;LT;LV;MK;RO;SI

RIN1 Inventor (correction)

Inventor name: CELIS, ESTEBAN

Inventor name: KUBO, RALPH, T.

Inventor name: SETTE, ALESSANDRO

Inventor name: LIVINGSTON, BRIAN, D.

Inventor name: SOUTHWOOD, SCOTT

Inventor name: CHESNUT, ROBERT

Inventor name: SIDNEY, JOHN

Inventor name: BAKER, DENISE, MARIE

A4 Despatch of supplementary search report

Effective date: 20050506

18D Deemed to be withdrawn

Effective date: 20071201